- Home
- NATH vs PBYI Comparison
NATH vs PBYI Comparison
Compare NATH & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NATH | PBYI |
|---|---|---|
| Founded | 1916 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 412.2M | 343.9M |
| IPO Year | 1996 | 2011 |
Fundamental Metrics
Financial Performance| Metric | NATH | PBYI |
|---|---|---|
| Price | $101.52 | $7.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.7K | ★ 244.4K |
| Earning Date | 06-09-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | ★ 22.29 | N/A |
| EPS | ★ 4.17 | N/A |
| Revenue | ★ $104,201,000.00 | $27,685,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.35 | ★ $11.93 |
| Revenue Growth | ★ 7.81 | N/A |
| 52 Week Low | $88.67 | $2.85 |
| 52 Week High | $118.32 | $7.90 |
Technical Indicators
Market Signals| Indicator | NATH | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 59.83 | 56.64 |
| Support Level | $100.25 | $7.09 |
| Resistance Level | $102.07 | $7.81 |
| Average True Range (ATR) | 0.42 | 0.33 |
| MACD | 0.05 | -0.05 |
| Stochastic Oscillator | 90.10 | 55.29 |
Price Performance
Historical ComparisonAbout NATH Nathan's Famous Inc.
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.